iSectra — Believe IT
PharmaceuticalCybersecurityMicrosoft

What Acquirers Actually Examine in Pharma IT Due Diligence

Most pharma companies treat IT as operational until the moment someone is buying them — and then it becomes a valuation matter. A buyer's-side view of what the diligence team opens first, and what it costs when the answers aren't there.

Roni Banerjee Aug 26, 2026 8 min read
What Acquirers Actually Examine in Pharma IT Due Diligence

IT due diligence in a pharma acquisition asks three things: whether the systems and data a company says it owns are actually transferable, whether the liabilities around them are known and disclosed, and whether operations survive the change of control. The single item that causes the most trouble is not any one of those — it is the undocumented environment, where the answers sit with one person or one outside provider and cannot be produced from a record. That is what pharma IT due diligence is really looking for, and almost everything else flows from it.

I lead investments and M&A at iSectra and have evaluated hundreds of companies for acquisition. What follows is a buyer's-side view — not a vendor explaining why you need better IT, but the questions a diligence team opens first, and what it costs when the answers aren't there.

Pharma IT Readiness Assessment

See where your regulated environment actually stands.

Fifteen questions, about five minutes, scored on screen with a remediation roadmap emailed to you.

Take the assessment

One of those companies was CinCor Pharma, which we supported from its first employee through IPO and on to acquisition — a clean example of what a documented environment makes possible when change of control arrives.

Why does IT come up in diligence at all?

A buyer is underwriting three things: that the assets are real and transferable, that the liabilities are known, and that operations survive the transition. IT touches all three. The data behind a clinical program is an asset. An unpatched vulnerability or an unresolved incident is a liability. The environment that runs day-to-day operations — email, file shares, the lab systems, the backups — has to keep running through a change of ownership or the deal has destroyed what it bought. IT is one of the few areas that appears in all three columns at once, which is why it gets opened early rather than late.

Who actually owns your systems and licenses?

This is where diligence surprises people most, so it goes first. Licenses purchased through an IT provider often sit in the provider's tenant, not yours. Microsoft 365 is the common example: a company pays for its seats, but if the partner set them up under the partner's own tenant and administers them from there, the buyer is looking at a rental arrangement dressed as ownership. Monitoring agents, endpoint security, backup software — these are frequently installed under the provider's accounts. Domain registrations sometimes sit in an employee's personal registrar account from the year the company was founded.

When a buyer finds that assets the company believed it owned are rented through a third party, the response is not anger. It is a working assumption that those assets may not transfer cleanly, and a line item for the cost and time of replacing or re-provisioning them. The company then has to go back to the provider and negotiate the assignment — often under deal pressure, often with the clock running.

Can you prove your IP is segregated and protected?

For a biotech, the research data is the asset being bought. The diligence team will ask where it lives, who has had access, whether that access is logged, and whether you can demonstrate it was never commingled with a partner's data or a CRO's. Shared workspaces are a recurring problem — a study folder that a contract research organization still has access to months after study close, or a platform instance shared across two programs because it was cheaper to stand up that way.

The buyer is not asking for perfection. They are asking for a record. Can you show who had access and when? Can you show that access was revoked at the right points? Can you show the data was never exported to a personal account or a shared drive outside your control? If the answer is "we'd have to ask our provider to pull that," the buyer has to price the cost of finding out — and the risk of what they might find.

Is your validated-system estate documented?

For a pharmaceutical or biotech company operating under GxP, the buyer will want the computerized system inventory, the risk classification of each system, the validation status, and the change control records. This is not a regulatory question — it is an integration question. The buyer is pricing what it will cost to bring your environment up to their standard, and the absence of documentation is priced as the maximum plausible cost, not the likely one.

A documented system that is partially out of date tells a buyer where they stand. An undocumented system tells them nothing, so they assume the worst and adjust accordingly. The gap between "we have a list and it's mostly right" and "we'd have to build one" is large in a deal — and small to close on a quiet Friday when there is no deal pressure.

What does key-person risk look like in IT?

The environment nobody but one person understands. Credentials not in a managed vault but in a spreadsheet, a notebook, or a single engineer's password manager. Custom scripts — PowerShell, shell, whatever holds a process together — that one person wrote and only one person can read. The buyer calls this key-person risk, and they discount for it explicitly because the fix, if the person leaves, is months of reconstruction.

The pattern the diligence team looks for is not the absence of a specialist. Specialists are expected. The problem is a critical dependency with no documentation and no fallback — a system whose continued operation depends on one person's memory. If that person is also the one who would be expected to explain the system during diligence, the buyer has to bring in outside help to verify what they're being told, and that cost and delay lands on the seller's side of the table.

What are your third-party and provider dependencies?

Contracts with auto-renewal clauses, termination terms, notice periods, and — the one that matters most in a transaction — whether the provider relationship is assignable on a change of control. A provider contract that cannot be assigned or terminated cleanly becomes a negotiation item. The buyer either inherits it on whatever terms it's on, or the seller has to negotiate a termination or assignment in the middle of the deal, which is rarely free.

The diligence team will read these contracts. Most companies have not. If your IT services agreement has a change-of-control provision you have not reviewed, that is the kind of thing that surfaces in diligence rather than in the quiet of a normal quarter — and it's worth reading the agreement before someone else does.

What security and compliance history will surface?

Prior incidents, breach notifications, unpatched known vulnerabilities, and partner security questionnaires answered inaccurately in the past. The diligence team will compare what you represented in your own responses to what the environment actually shows. Inaccurate historical answers are worse than gaps — a gap is a missing answer, but an inaccurate answer raises a question about everything else you've represented. If a security questionnaire said multi-factor authentication was enforced everywhere and the environment shows it wasn't, the buyer has to re-verify the rest of the questionnaire item by item.

What does this cost you in a deal?

The cost is rarely the remediation itself. It is the uncertainty the buyer prices in. Extended timelines while the diligence team waits for answers. Indemnity provisions written around the gaps. Escrow holdbacks — money set aside until a condition is met. Purchase-price adjustments when the cost of fixing the environment is large enough to move the number. Occasionally, a renegotiated price.

The mechanism matters more than any number. A clean set of answers keeps the deal on its timeline. A set of answers that keeps changing — new gaps surfacing as old ones are explained — extends the timeline and widens the gap between the price offered and the price the seller expected. The companies that come through cleanly are not the ones with the best IT; they are the ones whose IT is documented.

What diligence asks for, and what it costs when the answers aren't there

What diligence asks forWhy the buyer caresWhat it costs you if it's missing
License ownership confirmationAssets must be transferable, not rented through a providerRe-provisioning cost and delay during the deal
Microsoft 365 tenant ownershipThe tenant holds mail, files, and admin controlNegotiation with the provider to release the tenant
System inventory with risk classificationThe buyer prices the cost of integrationPriced at maximum plausible cost, not the likely one
Validation status and change control recordsDemonstrates the validated estate is maintainedAssumed non-compliant until proven otherwise
IP access logs and segregation evidenceThe research data is the asset being acquiredBuyer has to fund a forensic review
Credential management (managed vault)Key-person risk assessmentDiscount for reconstruction cost if the person leaves
Provider contract assignabilityChange of control may not transfer the relationshipNegotiation item, possible termination fees
Security questionnaire accuracyTrust in everything else you've representedRe-verification of the full questionnaire, item by item
Domain and DNS ownershipOperational continuity depends on itRe-registration, possible downtime, possible domain loss

What to fix now, cheaply

None of this is technically difficult. All of it takes time, and time is exactly what you don't have under deal pressure. The items below cost little today and a great deal to reconstruct later:

  1. 1.Maintain a system inventory. A living list of every system, what it does, who owns it, and where it's hosted. It does not need to be elaborate. It needs to exist and be kept current.
  2. 2.Confirm license ownership in writing. Ask your provider, in writing, which assets sit in your tenant and which sit in theirs. The answer is the document a buyer will ask for.
  3. 3.Move to individual named accounts. Shared accounts make access logging meaningless. Named accounts let you show who did what and revoke access cleanly at offboarding.
  4. 4.Document offboarding. A written process for what happens to access, credentials, and data when someone leaves. If it lives in one person's head, that is the key-person risk a buyer discounts for.
  5. 5.Put credentials in a managed vault. Not a spreadsheet, not a notebook, not one person's password manager. A vault with access logging and a recovery path.
  6. 6.Build an asset register. Hardware, software, domains, licenses — what you have, where it is, and what it's tied to. This is the document a buyer uses to confirm the assets are real.
  7. 7.Read your provider contracts. Specifically, the termination terms, the auto-renewal clauses, and the change-of-control provision. If the contract cannot be assigned cleanly, you want to know that now, not during diligence.

If you operate in pharma, the pharmaceutical industry page covers how these patterns show up in regulated environments specifically, and the seed-stage-to-IPO article traces how the documentation burden changes as a company grows — the two perspectives this article is written against.

The timing point

None of this is difficult, but all of it takes months to assemble under deal pressure. A system inventory built in a quiet quarter is a document. A system inventory built the week before diligence opens is a fire drill, and the buyer can tell the difference because the fire-drill version has gaps that the quiet-quarter version does not. The companies that come through diligence cleanly started two years earlier, usually without knowing that was what they were doing — they kept records because it was the right way to run a company, and the diligence team found those records waiting.


Photo by Van Tay Media on Unsplash.

Frequently asked questions

Don't see your question? Email info@isectra.com and we'll answer it directly.

Share
PharmaceuticalCybersecurityMicrosoft
Roni Banerjee
Chief Investment OfficerRoni Banerjee

Roni leads investments and M&A at iSectra and has evaluated hundreds of companies for acquisition over the past five years. This article is written from the buyer's side of the table.

Get the next post in your inbox.

Signal, once or twice a month. No spam — just the posts worth reading.

Let's see what your IT could feel like.

A senior engineer will review your environment and respond within 24 hours. No sales script, no obligation.

(845) 563-0346
Call